9:00am - 5:00pm

Our Opening Hours Mon. - Fri.

1.800.799.2234

Call Us For Free Consultation

Facebook

Twitter

Search
 

WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Top West Virginia Mesothelioma Lawyer | Law Firm | Attorney | GPW > WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Estimated reading time: < 1 min

Condition: Malignant Pleural Mesothelioma

Estimated Enrollment: 31

Gender: All

Min Age: 18 Years

Age Group: Adult, Older Adult

Current Status: Completed

Study Results: No Results Available

Outcome Measures: To assess the 1-year progression free survival in patients,  To confirm the immunogenicity of the WT-1 analog peptide vaccine,  To assess the utility of using the serum marker, overall survival

Interventions: WT-1-vaccine Montanide + GM-CSF, Montanide adjuvant + GM-CSF (This arm is closed)

Phase:

Study Type: Interventional

Study Design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double (Participant, Investigator),Primary Purpose: Treatment

Primary Completion Date: July 25, 2017

Completion Date: July 25, 2017

Last  Posted Date: November 5, 2018

Location: Memorial Sloan Kettering Cancer Center, New York, New York, United States

Website Link: https://ClinicalTrials.gov/show/NCT01265433

Was this article helpful?
Dislike 0